Immune thrombocytopenia, commonly called ITP, is a blood disorder where your immune system mistakenly attacks and destroys your own platelets, the tiny blood cells responsible for clotting. A normal platelet count ranges from 150,000 to 400,000 per microliter of blood. In ITP, that number drops below 100,000 and sometimes falls below 10,000, which is where the risk of serious spontaneous bleeding becomes significant.
How ITP Works in the Body
Your immune system produces antibodies that latch onto the surface of your platelets, essentially tagging them for destruction. These antibodies are primarily a type called IgG, and they target proteins that sit on the platelet surface. Once tagged, your platelets are recognized and consumed by immune cells called phagocytes, mostly in the spleen. The spleen, which normally filters old or damaged blood cells, becomes the primary site where both the rogue antibodies are produced and the marked platelets are destroyed.
The result is a platelet shortage. Your body may still produce platelets at a normal rate, but they’re cleared from your bloodstream far faster than they can be replaced. In some cases, the antibodies also attack the cells in bone marrow that produce platelets, further reducing your body’s ability to keep up.
Primary vs. Secondary ITP
ITP comes in two forms. Primary ITP develops on its own with no identifiable underlying cause. It’s a diagnosis of exclusion, meaning doctors rule out everything else first.
Secondary ITP is triggered by another condition or exposure. Common triggers include autoimmune diseases like lupus or antiphospholipid syndrome, infections such as HIV, hepatitis C, or cytomegalovirus, and certain cancers like lymphoma or chronic lymphocytic leukemia. Some medications can also cause it, including heparin, certain antibiotics, and quinine. In infection-related cases, the mechanism often involves molecular mimicry: your immune system makes antibodies against a virus, and those antibodies happen to cross-react with proteins on your platelets. Distinguishing between primary and secondary ITP matters because the treatment approach, expected course, and outcomes can differ substantially.
Symptoms and Warning Signs
Many people with mildly low platelet counts have no symptoms at all and discover ITP through a routine blood test. When symptoms do appear, they tend to involve bleeding that’s out of proportion to the injury, or bleeding that happens without any injury.
The most recognizable signs are skin-related. Petechiae are tiny, flat red or purple spots, often appearing on the lower legs, caused by blood leaking from small vessels under the skin. Purpura are larger patches of discoloration, red, purple, or brownish-yellow, from bleeding beneath the skin’s surface. Other common symptoms include frequent or hard-to-stop nosebleeds, bleeding gums, blood in urine or stool, and unusually heavy menstrual periods.
The platelet count where bleeding risk rises sharply is around 20,000 per microliter. Below 10,000, the risk of mucosal bleeding (from the gums, nose, or digestive tract) increases further. The most dangerous complication is bleeding in the brain, which is rare but can be life-threatening. People taking blood-thinning medications face roughly four times the risk of severe bleeding compared to those who aren’t.
How ITP Differs in Children and Adults
ITP behaves quite differently depending on age. In children, ITP often follows a viral infection and resolves on its own. About 80% of children experience spontaneous remission within three to six months. In adults, the picture is less favorable: only about 20% see their platelet counts recover without treatment. ITP that persists beyond one year is classified as chronic, and this is far more common in adults.
How ITP Is Diagnosed
There’s no single test that confirms ITP. Diagnosis relies on finding a low platelet count while ruling out other causes of thrombocytopenia (low platelets). Your doctor will review your medical history, check for infections or autoimmune conditions, review your medications, and examine your blood under a microscope to make sure the platelets themselves look normal. The goal is to confirm that the low count is immune-driven rather than caused by a bone marrow problem, medication side effect, or another condition.
First-Line Treatment
Not everyone with ITP needs treatment. If your platelet count is above 30,000 and you have no symptoms or only minor bruising, your doctor may recommend monitoring with regular blood tests rather than starting medication right away.
When treatment is needed, corticosteroids are the standard starting point. These medications suppress the immune response that’s driving platelet destruction. Most people see their platelet count rise within days to weeks, though counts often drop again when the medication is tapered. For faster results, particularly in emergencies, intravenous immunoglobulin can raise platelet counts within 24 to 48 hours by temporarily overwhelming the immune system’s ability to destroy tagged platelets.
Second-Line Options
If corticosteroids don’t produce a lasting response, several second-line therapies are available. Thrombopoietin receptor agonists work differently from other treatments: instead of suppressing the immune attack, they stimulate your bone marrow to produce more platelets, essentially outpacing the destruction. These are taken as ongoing medication.
Rituximab, a targeted therapy that reduces the specific immune cells producing the harmful antibodies, is another option. It works well for some patients but not all, and responses can take several weeks to develop.
Splenectomy, surgical removal of the spleen, remains one of the most effective treatments for ITP that doesn’t respond to medication. Because the spleen is where most platelet destruction occurs, removing it eliminates the primary site of the problem. About 80% of patients see an immediate platelet increase after surgery, and 66% to 72% maintain a lasting response at five or more years. However, splenectomy comes with trade-offs. Your spleen plays a key role in fighting certain bacterial infections. Even with vaccinations given before surgery, the infection rate is roughly 18 times higher than normal in the first 90 days after the operation. That risk decreases over time but remains about 2.5 times higher than the general population beyond the first year.
Living With ITP
Day-to-day management of ITP centers on reducing your bleeding risk. Contact sports like football, boxing, and martial arts should be avoided because a blow to the head could cause bleeding in the brain when platelet counts are low. Over-the-counter pain relievers like aspirin and ibuprofen thin the blood and increase bleeding risk, so acetaminophen is generally a safer alternative for pain management.
Beyond medication avoidance and activity modifications, living with ITP means staying aware of your platelet count trends and knowing what symptoms to watch for. New petechiae appearing without an obvious cause, unusually prolonged bleeding from minor cuts, or sudden severe headaches all warrant prompt attention. Many people with chronic ITP find a treatment regimen that keeps their counts in a safe range and live without major restrictions, but it often takes time and some trial and error to get there.